3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1/2
2
Phase 3
1
Phase 2/3
1
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Neuroblastoma
4
Central Nervous System Neoplasms
3
Small Cell Lung Carcinoma
2
Sarcoma
2
Ovarian Neoplasms
2
Neoplasms, Germ Cell and Embryonal
2
Multiple Myeloma
2
Lung Neoplasms
2
Leukemia
2
Hodgkin Disease
2
Brain Neoplasms
2
Teratoma
1
Seminoma
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Ovarian Germ Cell Cancer
1
Nonseminomatous germ cell tumor
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neoplasms, Unknown Primary
1
Neoplasms
1
Nasopharyngeal Neoplasms
1
Malignant mesenchymal tumor
1
Lymphoma, Non-Hodgkin
1
Lymphoma, B-Cell
1
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
1
Leukemia, Myelomonocytic, Acute
1
Leukemia, Myeloid, Acute
1
Leukemia, Monocytic, Acute
1
Leukemia, Megakaryoblastic, Acute
1
Interventions
Rituximab
14
pirtobrutinib
6
ibrutinib
4
Vincristine
4
Doxorubicin
4
Prednisone
3
Cytarabine
3
Cyclophosphamide
3
zanubrutinib
2
acalabrutinib
2
Methotrexate
2
Etoposide
2
Bendamustine Hydrochloride
2
venetoclax
1
tositumomab I-131
1
idelalisib
1
ibritumomab tiuxetan
1
etoposide phosphate
1
entecavir
1
cirmtuzumab
1
axicabtagene ciloleucel
1
VAP-cyclo protocol
1
Tenofovir
1
Radiotherapy
1
Melphalan
1
Ifosfamide
1
Gemcitabine
1
Everolimus
1
Drug Therapy
1
Dexamethasone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Lymphoma, B-Cell
×
etoposide phosphate
×
Clear all
NCT06230224
2026-05-11
OLYMPIA-4
Regeneron Pharmaceuticals
Phase 3
Active not recruiting
216 enrolled